Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $18,142 | 826 | 92.7% |
| Education | $1,266 | 18 | 6.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $157.33 | 8 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $2,684 | 89 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,800 | 58 | $0 (2024) |
| Biogen, Inc. | $1,397 | 77 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $1,216 | 50 | $0 (2024) |
| UCB, Inc. | $1,206 | 47 | $0 (2024) |
| GENZYME CORPORATION | $923.55 | 43 | $0 (2024) |
| ABBVIE INC. | $911.06 | 40 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $751.75 | 42 | $0 (2024) |
| Amgen Inc. | $746.29 | 27 | $0 (2024) |
| Lundbeck LLC | $658.08 | 36 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,010 | 122 | EMD Serono, Inc. ($443.38) |
| 2023 | $3,083 | 120 | EMD Serono, Inc. ($545.14) |
| 2022 | $2,393 | 102 | Neurocrine Biosciences, Inc. ($306.22) |
| 2021 | $1,581 | 74 | SK Life Science, Inc. ($243.66) |
| 2020 | $943.95 | 46 | EMD Serono, Inc. ($136.00) |
| 2019 | $2,372 | 122 | EMD Serono, Inc. ($317.74) |
| 2018 | $2,967 | 123 | Teva Pharmaceuticals USA, Inc. ($743.49) |
| 2017 | $3,216 | 143 | Teva Pharmaceuticals USA, Inc. ($519.25) |
All Payment Transactions
852 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.31 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Neurology | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $23.43 | General |
| Category: NEUROLOGY | ||||||
| 12/12/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: EPILEPSY | ||||||
| 12/12/2024 | NEUROPACE, INC. | RNS Neurostimulator Kit (Device) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Epilepsy | ||||||
| 12/10/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $30.92 | General |
| 12/09/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Neurology | ||||||
| 12/05/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: Neurology | ||||||
| 12/03/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Immune | ||||||
| 11/26/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $16.77 | General |
| Category: Neurology | ||||||
| 11/25/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $96.75 | General |
| 11/25/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: PAIN | ||||||
| 11/21/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Neuropsychiatry | ||||||
| 11/20/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.27 | General |
| 11/13/2024 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $16.49 | General |
| 11/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2024 | UCB, Inc. | Rystiggo (Drug) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/06/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/29/2024 | Alexion Pharmaceuticals, Inc. | KOSELUGO (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Oncology | ||||||
| 10/22/2024 | BANNER LIFE SCIENCES, LLC | BAFIERTAM (Drug) | Food and Beverage | In-kind items and services | $13.88 | General |
| Category: Immune | ||||||
| 10/08/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| Category: NEUROLOGY | ||||||
| 10/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.70 | General |
| Category: Neuropsychiatry | ||||||
| 10/04/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $26.95 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 209 | 318 | $175,320 | $36,206 |
| 2022 | 4 | 153 | 260 | $126,500 | $26,000 |
| 2021 | 7 | 234 | 359 | $174,105 | $34,186 |
| 2020 | 5 | 194 | 314 | $91,705 | $26,837 |
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 62 | 122 | $61,000 | $14,143 | 23.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 43 | 43 | $43,000 | $7,898 | 18.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 69 | $25,875 | $5,397 | 20.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 38 | 56 | $21,000 | $4,687 | 22.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 15 | $21,000 | $3,400 | 16.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 13 | $3,445 | $679.51 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 58 | 122 | $61,000 | $12,855 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 49 | 80 | $30,000 | $5,784 | 19.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $22,000 | $4,634 | 21.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 36 | $13,500 | $2,726 | 20.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 123 | $58,700 | $14,378 | 24.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 64 | 112 | $37,410 | $7,689 | 20.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 30 | 30 | $24,000 | $4,398 | 18.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 32 | 43 | $16,125 | $3,341 | 20.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 15 | 15 | $9,430 | $2,523 | 26.8% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2021 | 20 | 20 | $24,200 | $1,190 | 4.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 14 | 16 | $4,240 | $667.68 | 15.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 92 | 184 | $36,975 | $11,604 | 31.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 59 | 82 | $24,725 | $8,013 | 32.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 15 | $15,000 | $3,316 | 22.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $6,875 | $2,150 | 31.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 22 | $8,130 | $1,753 | 21.6% |
About Dr. Mary Downs, MD
Dr. Mary Downs, MD is a Neurology healthcare provider based in Anchorage, Alaska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750300794.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mary Downs, MD has received a total of $19,566 in payments from pharmaceutical and medical device companies, with $3,010 received in 2024. These payments were reported across 852 transactions from 66 companies. The most common payment nature is "Food and Beverage" ($18,142).
As a Medicare-enrolled provider, Downs has provided services to 790 Medicare beneficiaries, totaling 1,251 services with total Medicare billing of $123,228. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Anchorage, AK
- Active Since 07/19/2006
- Last Updated 07/01/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1750300794
Products in Payments
- TYSABRI (Biological) $1,063
- INGREZZA (Drug) $1,024
- Rebif (Biological) $935.06
- UBRELVY (Drug) $803.59
- Briviact (Drug) $585.98
- Aimovig (Biological) $538.44
- NUPLAZID (Drug) $512.01
- AUBAGIO (Drug) $446.13
- MAVENCLAD (Drug) $432.96
- VALTOCO (Drug) $393.71
- Fintepla (Drug) $328.03
- COPAXONE (Drug) $320.67
- ZEPOSIA (Drug) $311.51
- OCREVUS (Biological) $308.89
- XCOPRI (Drug) $291.52
- KESIMPTA (Drug) $284.97
- NORTHERA (Drug) $282.36
- VYEPTI (Biological) $258.60
- RYTARY (Drug) $256.22
- APTIOM (Drug) $248.30
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Anchorage
Stanford Downs, Md, MD
Neurology — Payments: $20,721
Mr. Scot Hines, M.d, M.D
Neurology — Payments: $8,684
Dr. David Henzler, Md, MD
Neurology — Payments: $8,385
Dr. Franklin Ellenson, Md, MD
Neurology — Payments: $2,368
Aaron Tauer, Md, MD
Neurology — Payments: $1,961
Marci Troxell, Do, DO
Neurology — Payments: $1,251